The review found no eligible studies for this question.
Antidepressants showed no clear difference in maintenance of remission at 12 months compared with placebo (low certainty).
It is very uncertain whether antidepressants changes endoscopic relapse at 12 months compared with placebo (very low certainty).
The review found no eligible studies for this question.
Antidepressants may leads to lower failure to respond compared with placebo (low certainty).
Antidepressants probably leads to lower total number of dropouts compared with placebo (moderate certainty).
Antidepressants probably leads to lower failure to remit compared with placebo (moderate certainty).
Antidepressants probably leads to higher number of dropouts due to adverse effects compared with placebo (moderate certainty).
Antidepressants showed no clear difference in failure to respond compared with benzodiazepines (low certainty).
It is very uncertain whether antidepressants changes total number of dropouts compared with benzodiazepines (very low certainty).
Antidepressants probably leads to higher failure to remit compared with benzodiazepines (moderate certainty).
Antidepressants may leads to higher number of dropouts due to adverse effects compared with benzodiazepines (low certainty).
Antidepressants showed no clear difference in dropout ‐ Dropouts: excluding studies with high risk of bias objective compared with placebo according to any definition (moderate certainty).
Antidepressants showed no clear difference in abstinence, for at least three consecutive weeks objective compared with placebo according to any definition (high certainty).
Antidepressants showed no clear difference in adverse events ‐ Withdrawn due to adverse events compared with placebo according to any definition (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether SSRI antidepressants changes drop‐outs (12 weeks) compared with TCA (very low certainty).